We specialize in the construction of 4th-generation TRUCKs (T-cells redirected for universal cytokine-mediated killing) and 5th-generation CARs. These designs incorporate STAT3 binding sites and JAK/STAT signaling domains to maintain the "stemness" of the CAR-T cells themselves, ensuring they remain active throughout the duration of the study.
Cancer Stem Cell targeted CAR-T Design & Validation Service
Creative Biolabs provides a specialized pipeline to bridge the gap between target identification and validated preclinical leads. We transform "undruggable" hubs like Notch, Wnt, and Hedgehog into high-precision immunotargeting opportunities by engineering immune cells with the fitness to survive the metabolic barriers of the solid tumor microenvironment (TME). Our platform focuses on multi-specific chimeric antigen receptors (CARs) to prevent antigen escape in cancer stem cells (CSCs). This ensures definitive data through limiting dilution assays and serial transplantation, validating your candidate's ability to achieve a "true cure" in vivo.
Background What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Strategic Engineering: From 1st to 5th Generation CARs
Creative Biolabs overcomes CSC research hurdles, marker cross-reactivity, and T-cell exhaustion through a multi-tiered CAR design strategy. Our 4th Gen (TRUCKs) secrete IL-12/18 to remodel the immunosuppressive TME, while 5th Gen architectures incorporate JAK/STAT signaling to ensure long-term persistence in longitudinal studies. To eliminate primary cell variability, we provide standardized induced pluripotent stem cell (iPSC)-derived CAR-T platforms. These high-throughput, "off-the-shelf" research batches utilize CRISPR/Cas9 precision editing to insert CARs into defined loci, significantly improving regression in xenograft models and reducing exhaustion for robust preclinical validation.
End-to-End Preclinical Discovery
Creative Biolabs offers an exhaustive suite of engineering and validation tools tailored to the unique biology of CSCs. Our offerings are designed to provide a turnkey solution for biopharmaceutical research teams:
Next-Generation CAR Architectures
Precision Targeting Modules
Our platform includes the development of logic-gated (AND, OR, NOT) circuits. These are critical for targeting markers like CD133, CD44v6, or EpCAM while sparing healthy adult stem cell populations, thereby maximizing the therapeutic index.
"Armored" Immune Cells
We offer engineering services for the secretion of ECM-modifying enzymes such as Heparanase and pro-inflammatory cytokines like IL-12 and IL-15. This "armoring" allows engineered cells to breach the dense fibrotic matrix protecting the CSC niche.
iPSC-Derived Cellular Backbones
For standardized research, we offer iPSC-derived CAR-T and CAR-NK platforms. These clonal populations remove the donor-to-donor variability inherent in primary cells, providing a consistent baseline for high-throughput screening and comparative efficacy studies.
Unlock the Potential of Your Oncology Pipeline — Inquire About Our Engineered CAR Solutions
A Systematic Approach to CSC Eradication
To ensure the highest levels of reproducibility and scientific rigor, Creative Biolabs employs a streamlined, data-driven workflow.
Publication
This review explores the critical role of CSCs in tumor persistence and relapse, highlighting CAR-based immunotherapies as a promising strategy to target these resilient cells. It examines CSC biology, specific antigens, and preclinical and clinical applications across various cancers, while addressing key challenges like tumor microenvironment suppression and antigen specificity. The discussion concludes with future directions, including dual-targeting approaches and AI-driven advancements, aiming to enhance therapeutic efficacy and achieve durable cancer remissions.
Fig.1 The spectrum of CAR-armored immune effectors in cancer therapy. 1
Why Choose Us?
Creative Biolabs stands at the forefront of CSC research, offering a unique "discovery-to-validation" ecosystem. Our advantage lies in our 5th-generation CAR platform, which addresses the primary cause of CAR-T failure in solid tumors: exhaustion. We utilize published data to benchmark our logic-gated systems, ensuring that your leads possess the highest possible specificity. Furthermore, our ability to integrate multiple modifications, such as metabolic reprogramming and epigenetic tuning, allows for a truly "environment-aware" therapeutic candidate. Our success is documented through numerous collaborative breakthroughs where we have enabled research groups to overcome the "recurrence bottleneck." By choosing Creative Biolabs, you gain access to a team that understands the nuances of CSC biology and the technical rigor required for high-impact oncology research.
Experience the Creative Biolabs Advantage — Get a Detailed Quote Today
FAQs
How do you ensure CAR-T cells don't target normal adult stem cells?
We utilize affinity-tuned scFvs and logic-gated "AND" circuits that require two markers for activation, ensuring the CAR only triggers upon encountering the unique signature of a CSC.
Can you target intracellular CSC markers like ALDH or Notch?
While CARs typically target surface antigens, we offer TCR-like CARs and specialized delivery systems to target peptides derived from these intracellular signaling hubs.
What is the benefit of using iPSC-derived cells for CSC research?
iPSCs provide a standardized, clonal source of cells, removing the variability found in primary T-cells and allowing for high-throughput, reproducible experimental results.
Customer Review
-
Superior Specificity
The logic-gated AND-gate design solved our cross-reactivity issues with healthy hematopoietic stem cells. Our CSC-targeted project is finally moving forward with clean safety data. - Prof. Ma** K -
Definitive Validation
The serial transplantation data provided by their team was the cornerstone of our recent high-impact publication. It is the only way to truly prove CSC eradication. - Dr. He** L
Related Services
Cancer Stem Cell Specific Peptide Vaccine Development
Creative Biolabs offers CSC-specific peptide vaccine development, targeting unique neoantigens and stemness markers. We utilize advanced adjuvant platforms to break immune tolerance and eradicate self-renewing tumor populations.
Learn More →Antibody Maturation Service
Creative Biolabs provides antibody affinity maturation services, combining molecular evolution with high-throughput phage display. We significantly enhance antibody potency and binding kinetics.
Learn More →How to Contact Creative Biolabs
Creative Biolabs provides a world-class environment for the design, engineering, and preclinical validation of CAR-T cells specifically tuned to eradicate CSCs. From 5th-generation signaling to serial transplantation validation, we ensure your program is built on the most robust scientific foundation possible.
For detailed technical specifications or to discuss your specific tumor model, please reach out to our senior scientific team.
Reference
- Hadiloo, Kaveh, et al. "Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions." Cancer Cell International 25.1 (2025): 289. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1186/s12935-025-03846-3
Download our brochureLoading case studies...
Online Inquiry